• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    V

    VieCuri Medisch Centrum

    799论文总数
    2万引用总数

    论文量&引用量时间轴

    机构学者

    论文(799)

    年份
    起
    –
    止
    排序
    1Combined Strategy of Upfront CTCA and Optimal Treatment for Stable Chest Pain: Rationale and Design of the CLEAR-CAD Trial.
    Victor A. Verpalen,Casper F. Coerkamp, Mark J. Hinderks,Joan G. Meeder,Michiel M. Winter,E. Karin Arkenbout,Jeroen C. Vis,Jesse Habets,Martijn W. Smulders,Casper Mihl, Clara E. E. van Ofwegen-Hanekamp, Tycho I. G. van der Spoel,

    Patients with stable chest pain suspected of coronary artery disease (CAD) usually undergo multiple diagnostic tests to confirm or rule out obstructive CAD. Some tests may not effectively assess the presence of CAD, precluding optimal treatment. A diagnostic strategy of upfront computed tomography coronary angiography (CTCA) combined with optimal medical therapy (OMT) tailored to the extent of CAD may be superior to standard care in preventing major adverse cardiac events. The CLEAR-CAD trial is a prospective, open-label, multicentre, randomised, superiority trial of an upfront CTCA-guided strategy in 6444 patients presenting in an outpatient setting with suspected CAD compared with standard care, in approximately 30 participating centres in the Netherlands. The upfront CTCA-guided strategy consists of an initial CTCA which is assessed using the Coronary Artery Disease-Reporting and Data System (CAD-RADS 2.0). In patients without CAD (CAD-RADS 0) no specific cardiac medication is mandated. Patients with non-obstructive CAD (CAD-RADS 1–2) are treated with preventive OMT. Patients with obstructive CAD (CAD-RADS ≥ 3) are treated with preventive and anti-anginal OMT; in the presence of pharmacologically refractory symptoms patients undergo selective revascularisation after non-invasive functional imaging for myocardial ischaemia (≥ 10

    2026Netherlands Heart Journal(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2‘Werkgevers: Ondersteun Je Nachtwerkers Beter'
    Caroline Mostart
    2026Nursing(2026)
    引用
    AI阅读
    加入学术空间
    3The Effect of Preoperative High-Intensity Functional Interval Training on Outcomes in Lumbar Spinal Fusion
    E. van Leent, M. Hulsbosch, A. Smeets, F. Lambers Heerspink, P. Willems, E. Janssen
    2026Brain and Spine(2026)
    引用
    AI阅读
    加入学术空间
    4Changes in Taste and Smell Function During Adjuvant Chemotherapy in Patients with Colon Cancer: a Prospective Cohort Study
    K. Beukers,A.J. van de Wouw, R.C. Havermans,M.L.G. Janssen-Heijnen

    Background & aims Adjuvant chemotherapy for high-risk stage II or stage III colon cancer improves survival, but frequently induces side effects, including changes in taste (hypogeusia) and smell (hyposmia) function. These alterations in taste and smell function may reduce appetite and nutritional intake, increasing the risk of malnutrition and compromising treatment tolerance and quality of life. Objective data on these changes during chemotherapy are limited. The aim of this study was to investigate changes in taste and smell function during adjuvant chemotherapy in patients with colon cancer. Methods In this relatively small prospective cohort study, eleven patients with high-risk stage II or III colon cancer receiving capecitabine or CAPOX were included. Taste and smell function were assessed using Taste Strips and Sniffin’ Sticks before, during, and after chemotherapy. Paired-samples t-tests compared taste and smell function at each time point to baseline. Results Significant declines in taste (T1; mean difference = -1.33, p = 0.022) and smell (T1; mean difference = -5.11, p = 0.017) were observed after the first chemotherapy cycle. Baseline hypogeusia and hyposmia were present in 33% and 44% of patients, respectively. During treatment, hypogeusia ranged from 33–44% and hyposmia from 44–78%, with marked inter- and intra-individual variability. While most patients maintained normogeusia, hyposmia was more common at multiple time points. Conclusion Adjuvant chemotherapy is associated with clinically relevant, but heterogeneous changes in taste and smell, particularly during the initial phase of chemotherapy. These alterations may impair nutritional intake, highlighting the need for early, individualized dietary interventions. Combining objective and patient-reported assessments may optimize supportive care, enhancing treatment tolerance and quality of life. Despite the small sample size, which substantially limits generalizability, the in-depth analysis highlights significant variability in taste and smell function both between patients and across chemotherapy cycles, highlighting that chemosensory changes are neither uniform nor static.

    2026Clinical Nutrition Open Science(2026)
    引用
    AI阅读
    加入学术空间
    5Benchmarking Missing-Data-Native Survival Models in a Real-World Metastatic NSCLC Cohort — the AI-HOPE Lung Cancer Study
    Francesca Rita Ogliari, Donato Tiano,Alberto Traverso, Patrick Scuri, Daniele Celada, Simone Barbieri, Giulio Cielo, Michele Ferrara, Ludovica Papotto, Jarno Huijs, Magdolen Youssef El-Soud, Christi M. J. Steendam,

    Prognostic estimation for patients with metastatic non-small cell lung cancer remains challenging in real-world settings, where heterogeneous clinical workflows and structured missing data limit the applicability of traditional models. In the AI-HOPE Lung Cancer study, we benchmarked multiple time-to-event machine learning models with native missing-value handling in a multicenter cohort of 626 patients treated with first-line immunotherapy-based regimens. Model performance was moderate but consistent with other advanced oncology settings, reflecting the intrinsic complexity of survival prediction in metastatic disease. Discrete-time and ensemble tree-based models demonstrated robust calibration, while maintaining competitive discrimination. Importantly, inflammatory markers and established clinical variables (ECOG, PD-L1) emerged as stable prognostic factors across architectures. Our findings support the use of missing-aware survival models as a scalable and clinically meaningful approach for real-world, multicenter oncology, providing a foundation for future multimodal integration and prospective validation.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 799 篇论文

    合作机构(100)

    马斯特里赫特大学合作论文 315
    Catharina Ziekenhuis合作论文 79
    阿姆斯特丹大学合作论文 77
    奈梅亨拉德布大学合作论文 75
    Maaslandziekenhuis合作论文 65
    St. Antonius Ziekenhuis合作论文 52
    格罗宁根大学医学中心合作论文 49
    乌得勒支大学医学中心合作论文 48
    莱顿大学合作论文 43
    Rijnstate Hospital合作论文 36

    机构统计